Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

LAVA Therapeutics Q2 EPS $(0.48) Misses $(0.47) Estimate, Sales $5.14M Beat $830.00K Estimate

Author: Benzinga Newsdesk | August 22, 2023 07:17am
LAVA Therapeutics (NASDAQ:LVTX) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.47) by 2.13 percent. This is a 54.84 percent decrease over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $5.14 million which beat the analyst consensus estimate of $830.00 thousand by 519.28 percent. This is a 998.29 percent increase over sales of $468.00 thousand the same period last year.

Posted In: LVTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist